Close Menu

NEW YORK (GenomeWeb) – ERS Genomics today announced that it has non-exclusively licensed patents related to CRISPR-Cas9 genome-editing technology to Regeneron Pharmaceuticals for use in drug discovery and development.

Specific terms of the deal were not disclosed.

ERS was founded to provide broad access to the intellectual property, which is based on the research of Emmanuelle Charpentier from the Hannover Medical School in Germany and Umea University in Sweden.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Nature News reports that recent proposed changes to the US National Science Foundation have raised concerns about a shift away from the agency's focus on basic research.

Noel Rose, the "father of autoimmunity," has died at 92, the Washington Post reports.

According to CNN, Legionella was discovered in buildings leased by the Centers for Disease Control and Prevention as they reopened following coronavirus pandemic-related closures.

In PLOS this week: genetic analysis of malaria parasite populations in Southeast Asia, genomic surveillance of yellow fever virus in São Paulo, and more.